Individualized Diagnostics

Inostics has the goal to improve cancer drug development and standard patient management by offering state of the art molecular diagnostic tools for the non-invasive detection and monitoring of tumors in blood samples.

The core competency of Inostics is centered around the detection of genetic changes, such as somatic mutations, in a patients’ blood or tissue.

Sensitive Mutation Detection

image 2BEAMing Technology for the detection of mutations in Plasma/Serum and Tissue. more >>

Mutation Discovery

image 1Exon Sequencing for discovery and detection of mutations from tumor tissue. more >>

Companion Diagnostics Development

image 3Design, implementation and qualification of new companion diagnostics. more >>

Latest News

May 1, 2012

BEAMing Digital PCR Technology applied to blood-based mutation detection in breast cancer patients more >>

July 25, 2011

Inostics GmbH has successfully passed the external proficiency test for KRAS more >>

View all news >>